Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest medullary thyroid cancer Stories

2011-04-06 15:24:00

Vandetanib is first drug approved for medullary thyroid cancer SILVER SPRING, Md., April 6, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Thyroid cancer is a cancerous growth of the thyroid gland, which is...

2011-02-01 23:40:25

Positron emission tomography (PET) can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine. Currently being tested in clinical trials, vandetanib inhibits the function of the RET (rearranged-during-transfection protein) proto-oncogene and other protein kinases involved in the...

2010-12-28 08:21:30

(Ivanhoe Newswire) "“ Variations of a gene are associated with a type of tumor that forms within the adrenal gland, and were found in an age group uncommon for these types of tumors. Pheochromocytomas and paragangliomas are types of tumors. Pheochromocytomas form in the adrenal gland causing it to make too much adrenaline. Pheochromocytomas can cause high blood pressure, pounding headaches, heart palpitations, flushing of the face, nausea, and vomiting. Paragangliomas are rare, usually...

2010-12-02 14:16:00

WILMINGTON, Del., Dec. 2, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC). (Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO ) The Advisory...

2010-09-23 01:00:00

LONDON, Sept. 23 /PRNewswire/ -- AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011. (Logo:...

2010-06-07 08:14:00

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001). The results of the ZETA study were presented today at the American Society of Clinical Oncology...

2010-05-18 12:28:01

Individuals with papillary thyroid cancer that has not spread beyond the thyroid gland appear to have favorable outcomes regardless of whether they receive treatment within the first year after diagnosis, according to a report in the May issue of Archives of Otolaryngology"“Head & Neck Surgery, one of the JAMA/Archives journals. Papillary thyroid cancer is commonly found on autopsy among individuals who died of other causes, according to background information in the article....

2009-11-06 12:43:13

People living in volcanic areas may be at a higher risk for thyroid cancer, according to a new study published online November 5 in the Journal of the National Cancer Institute. The increasing incidence of thyroid cancer has been attributed to more sensitive screening, but recent evidence indicates that this may not be the only cause. Various environmental factors, such as those associated with volcanoes, have not been excluded as risk factors. To study this, Gabriella Pellegriti, M.D.,...

2009-10-19 17:12:58

In a study of patients undergoing thyroid surgery performed by a single surgeon, older adults did not appear to have more complications than younger patients, according to a report in October issue of Archives of Otolaryngology"“Head & Neck Surgery, one of the JAMA/Archives journals. The segment of the U.S. population older than 65 has increased by 90 percent during the past 30 years, according to background information in the article. "As the population ages, surgery is being...

2009-08-19 15:55:00

Journal of the American College of Surgeons study cites safer and easier operation with less scarring Using a novel robot-assisted endoscopic technique, a team of surgeons at Yonsei University College of Medicine in Seoul, Korea, has successfully treated 200 consecutive patients with thyroid cancer. The minimally invasive operation, which has several technical and cosmetic benefits that the traditional open operation does not offer, is described in the August issue of the Journal of the...